Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Amyotrophic Lateral Sclerosis | 31 | 2024 | 1469 | 4.510 |
Why?
|
Motor Neuron Disease | 4 | 2022 | 97 | 1.030 |
Why?
|
Creatine | 1 | 2019 | 427 | 0.580 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2015 | 60 | 0.490 |
Why?
|
Tamoxifen | 1 | 2019 | 965 | 0.480 |
Why?
|
Motor Neurons | 4 | 2022 | 870 | 0.420 |
Why?
|
Receptors, GABA | 4 | 2024 | 313 | 0.420 |
Why?
|
Carbon Radioisotopes | 4 | 2020 | 561 | 0.370 |
Why?
|
Taurochenodeoxycholic Acid | 2 | 2020 | 35 | 0.360 |
Why?
|
Oligonucleotides, Antisense | 2 | 2024 | 461 | 0.360 |
Why?
|
Muscular Diseases | 1 | 2015 | 553 | 0.360 |
Why?
|
Phenylbutyrates | 2 | 2020 | 72 | 0.350 |
Why?
|
Acetamides | 3 | 2024 | 256 | 0.340 |
Why?
|
Autoimmune Diseases | 2 | 2022 | 2244 | 0.290 |
Why?
|
Positron-Emission Tomography | 7 | 2024 | 6485 | 0.260 |
Why?
|
Pyridines | 4 | 2024 | 2875 | 0.250 |
Why?
|
Double-Blind Method | 7 | 2024 | 12341 | 0.240 |
Why?
|
Hydrazones | 1 | 2024 | 103 | 0.230 |
Why?
|
Spinal Cord | 2 | 2022 | 1819 | 0.210 |
Why?
|
Meninges | 1 | 2024 | 198 | 0.210 |
Why?
|
Electromyography | 2 | 2018 | 1394 | 0.200 |
Why?
|
Neurodegenerative Diseases | 2 | 2022 | 1088 | 0.200 |
Why?
|
Pyrazoles | 2 | 2024 | 2009 | 0.200 |
Why?
|
Muscle, Skeletal | 1 | 2017 | 4948 | 0.190 |
Why?
|
Pyrimidines | 3 | 2024 | 3028 | 0.190 |
Why?
|
Morpholines | 1 | 2024 | 581 | 0.190 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3245 | 0.170 |
Why?
|
Spastic Paraplegia, Hereditary | 1 | 2021 | 168 | 0.160 |
Why?
|
Recruitment, Neurophysiological | 1 | 2018 | 33 | 0.160 |
Why?
|
Muscle Strength | 2 | 2019 | 624 | 0.150 |
Why?
|
Atrophy | 1 | 2022 | 1633 | 0.140 |
Why?
|
Fluorine Radioisotopes | 1 | 2020 | 418 | 0.140 |
Why?
|
Videoconferencing | 1 | 2019 | 203 | 0.140 |
Why?
|
Vital Capacity | 1 | 2019 | 971 | 0.140 |
Why?
|
Running | 1 | 2021 | 488 | 0.130 |
Why?
|
Lumbosacral Region | 1 | 2017 | 293 | 0.120 |
Why?
|
Humans | 36 | 2024 | 761572 | 0.120 |
Why?
|
Histone Deacetylases | 1 | 2019 | 720 | 0.120 |
Why?
|
Aged | 16 | 2024 | 169310 | 0.120 |
Why?
|
Neuroprotective Agents | 1 | 2020 | 957 | 0.110 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2021 | 3769 | 0.110 |
Why?
|
Middle Aged | 17 | 2024 | 220920 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1202 | 0.110 |
Why?
|
Autoantibodies | 1 | 2022 | 2116 | 0.110 |
Why?
|
Adult | 16 | 2024 | 221203 | 0.100 |
Why?
|
Neuroglia | 1 | 2017 | 956 | 0.100 |
Why?
|
Motor Cortex | 1 | 2019 | 1007 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1809 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 867 | 0.090 |
Why?
|
Brain | 6 | 2021 | 27120 | 0.090 |
Why?
|
Necrosis | 1 | 2015 | 1611 | 0.090 |
Why?
|
Male | 19 | 2024 | 360842 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 36429 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2021 | 3826 | 0.080 |
Why?
|
Cohort Studies | 4 | 2021 | 41493 | 0.080 |
Why?
|
Multiple Sclerosis | 1 | 2024 | 3220 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2273 | 0.080 |
Why?
|
Female | 17 | 2024 | 392686 | 0.080 |
Why?
|
Diffusion Tensor Imaging | 1 | 2018 | 2400 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.070 |
Why?
|
Immunotherapy | 1 | 2022 | 4652 | 0.070 |
Why?
|
United States Food and Drug Administration | 2 | 2024 | 1664 | 0.060 |
Why?
|
Disease Progression | 4 | 2022 | 13510 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2024 | 64684 | 0.060 |
Why?
|
Linoleic Acids | 1 | 2022 | 39 | 0.050 |
Why?
|
Drugs, Investigational | 1 | 2024 | 212 | 0.050 |
Why?
|
Injections, Spinal | 1 | 2022 | 318 | 0.050 |
Why?
|
Telemedicine | 1 | 2019 | 3052 | 0.050 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2024 | 254 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 59255 | 0.050 |
Why?
|
Esters | 1 | 2022 | 211 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58986 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2024 | 793 | 0.050 |
Why?
|
Neurofilament Proteins | 1 | 2022 | 336 | 0.040 |
Why?
|
Gait Disorders, Neurologic | 1 | 2022 | 240 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 413 | 0.040 |
Why?
|
United States | 5 | 2024 | 72335 | 0.040 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 556 | 0.040 |
Why?
|
Time | 1 | 2020 | 546 | 0.040 |
Why?
|
Sick Leave | 1 | 2019 | 105 | 0.040 |
Why?
|
Adamantane | 1 | 2019 | 148 | 0.040 |
Why?
|
Electrodiagnosis | 1 | 2018 | 148 | 0.040 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2022 | 664 | 0.040 |
Why?
|
Sodium Chloride | 1 | 2018 | 587 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8633 | 0.030 |
Why?
|
Hydroxamic Acids | 1 | 2019 | 481 | 0.030 |
Why?
|
Algorithms | 1 | 2017 | 14032 | 0.030 |
Why?
|
Cerebral Cortex | 2 | 2024 | 5779 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1157 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2021 | 935 | 0.030 |
Why?
|
Housing | 1 | 2019 | 670 | 0.030 |
Why?
|
Fatty Acids | 1 | 2022 | 1808 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2048 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2218 | 0.030 |
Why?
|
Cost Savings | 1 | 2019 | 913 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1668 | 0.030 |
Why?
|
Travel | 1 | 2019 | 796 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2019 | 815 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2024 | 10766 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2019 | 4575 | 0.020 |
Why?
|
Recovery of Function | 1 | 2022 | 2979 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15843 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3725 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1936 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5247 | 0.020 |
Why?
|
Histones | 1 | 2019 | 2580 | 0.020 |
Why?
|
Biomedical Research | 1 | 2024 | 3429 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2019 | 2775 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2019 | 26127 | 0.020 |
Why?
|
Caregivers | 1 | 2019 | 2238 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5440 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2022 | 12975 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9177 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2791 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10212 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2019 | 12794 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8002 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13367 | 0.010 |
Why?
|
Brain Mapping | 1 | 2018 | 6635 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88324 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20099 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14607 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.010 |
Why?
|
Time Factors | 1 | 2023 | 39970 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2018 | 9002 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2018 | 80646 | 0.010 |
Why?
|
Concepts
(127)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_